ArticleJournal of the American Academy of Dermatology2020
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 4 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Time to Disease Control with Dupilumab for Bullous Pemphigoid: A Systematic Review and Meta-analysis.Acta dermato-venereologica · 2025Pooled it
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.Frontiers in immunology · 2022Pooled it
- Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis.Anais brasileiros de dermatologiaPooled it
- Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.Frontiers in immunology · 2023Trial
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin.The American journal of tropical medicine and hygiene · 2026Article
- Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study.The Journal of dermatology · 2026Observational
- Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature.Skin health and disease · 2026Review
- Successful Treatment of Bullous Pemphigoid Complicated by Possible Infective Endocarditis With Dupilumab Monotherapy: A Case Report.The Journal of dermatology · 2026Article
- Treatment patterns for bullous pemphigoid in older adults: A population-based study.Dermatology online journal · 2026Article
- Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients.Dermatology (Basel, Switzerland) · 2026Article
- Autoimmune Bullous Diseases: Therapeutic Update.Drugs · 2026Review
- Hemidesmosome Mutations Contribute to the Onset and Severity of Acquired Autoimmune Bullous Diseases.MedComm · 2026Article
- A Specific Signature of Circulating Free Fatty Acid Discriminates Bullous Pemphigoid From Pemphigus Vulgaris and Healthy Controls.Experimental dermatology · 2026Article
- Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.Postepy dermatologii i alergologii · 2026Article
- Case Report: Dupilumab as a corticosteroid-sparing adjunct in severe mucocutaneous pemphigus vulgaris with prior avascular necrosis and chronic kidney disease.Frontiers in medicine · 2026Article
- Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics.Journal of inflammation research · 2026Article
- Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly.Frontiers in immunology · 2026Article
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: A case study.Human vaccines & immunotherapeutics · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBullous pemphigoid (BP) is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments.
objectiveTo describe our experience using dupilumab in a series of patients with BP.
methodsThis is a case series of patients from 5 academic centers receiving dupilumab for BP. Patients were eligible if they had a clinical diagnosis of BP confirmed by lesional skin biopsy evaluated by one of more of the following: hematoxylin and eosin staining, direct immunofluorescence, or enzyme-linked immunosorbent assay for BP180 or BP230, or both.
resultsWe identified 13 patients. Patients were an average age of 76.8 years, and the average duration of BP before dupilumab initiation was 28.8 months (range, 1-60 months). Disease clearance or satisfactory response was achieved in 92.3% (12 of 13) of the patients. Satisfactory response was defined as clinician documentation of disease improvement and patient desire to stay on the medication without documentation of disease clearance. Total clearance of the BP was achieved in 53.8% (7of 13) of patients No adverse events were reported. LIMITATIONS: Include small sample size, lack of a control group, lack of a standardized assessment tool, and lack of standardized safety monitoring.
conclusionDupilumab may be an additional treatment for BP, leading to disease clearance or satisfactory response in 92.3% of patients, including in those in whom previous conventional therapy had failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.